AR029815A1 - Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento - Google Patents
Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamentoInfo
- Publication number
- AR029815A1 AR029815A1 ARP010101008A ARP010101008A AR029815A1 AR 029815 A1 AR029815 A1 AR 029815A1 AR P010101008 A ARP010101008 A AR P010101008A AR P010101008 A ARP010101008 A AR P010101008A AR 029815 A1 AR029815 A1 AR 029815A1
- Authority
- AR
- Argentina
- Prior art keywords
- nitrogen
- derivatives
- preparation
- alkyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados de aza-indolicos que comprenden un compuesto de la formula (1) en la cual n es 1, 2 o 3; X1 es nitrogeno o CR4; X2 es nitrogeno o CR5; X3 es nitrogeno o CR6; X4 es nitrogeno o CR7; en la cual uno o dos de los grupos X1, X2, X3 y X4 son nitrogeno; R1 y R2 se seleccionan independientemente entre hidrogeno y alquilo; R3 es hidrogeno o alquilo; R4 a R7 se seleccionan independientemente entre hidrogeno, halogeno, hidroxi, alquilo, arilo, alcoxi, ariloxi, alquiltio, ariltio, alquilsulfonilo, alquilsulfoxilo, arilsulfonilo, arilsulfoxilo, amino, monoalquilamino, dialquilamino, nitro, ciano, carboxaldehído, alquilcarbonilo, arilcarbonilo, aminocarbonilo, monoalquilaminocarbonilo, dialquilaminocarbonilo, alcoxicarbonilamino, aminocarboniloxi, monoalquilaminocarboniloxi, dialquilaminocarboniloxi, monoalquilamino- carbonilamilno y dialquilaminocarbonilamino, y en el cual un átomo de carbono del anillo proximo a un nitrogeno no está sustituido por halogeno; y sales y prodrogas farmacéuticamente aceptables del mismo. Un método para su preparacion, composicion farmacéutica, un método para su elaboracion y al uso de los mismos para la fabricacion de un medicamento en terapia, particularmente para el tratamiento de trastornos del sistema nervioso central; deterioro del sistema nervioso central; trastornos cardiovasculares; trastornos gastrointestinales; diabetes insípida y apnea del sueno, y particularmente para el tratamiento de la obesidad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00301814A EP1132389A1 (en) | 2000-03-06 | 2000-03-06 | New aza-indolyl derivatives for the treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
AR029815A1 true AR029815A1 (es) | 2003-07-16 |
Family
ID=8172768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101008A AR029815A1 (es) | 2000-03-06 | 2001-03-02 | Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento |
Country Status (15)
Country | Link |
---|---|
US (1) | US6583134B2 (es) |
EP (2) | EP1132389A1 (es) |
JP (1) | JP3828422B2 (es) |
KR (1) | KR100554817B1 (es) |
CN (1) | CN1281608C (es) |
AR (1) | AR029815A1 (es) |
AT (1) | ATE326470T1 (es) |
AU (2) | AU4067001A (es) |
BR (1) | BR0109044A (es) |
CA (1) | CA2399111A1 (es) |
DE (1) | DE60119719T2 (es) |
ES (1) | ES2263595T3 (es) |
MX (1) | MXPA02008689A (es) |
WO (1) | WO2001066548A1 (es) |
ZA (1) | ZA200206198B (es) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2291374T3 (es) * | 2000-12-27 | 2008-03-01 | F. Hoffmann-La Roche Ag | Derivados de indol y su empleo como ligandos receptores de 5-ht2b y 5-ht2c. |
CN100484933C (zh) | 2002-06-19 | 2009-05-06 | 比奥维特罗姆股份公开公司 | 新的吡嗪化合物及其在制备用于治疗与5-羟色胺相关的疾病的药物中的用途 |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
GB0314967D0 (en) | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Msd株式会社 | 新規ピペリジン誘導体 |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
KR100592805B1 (ko) * | 2004-04-13 | 2006-06-26 | 한국화학연구원 | 인덴 유도체 및 이의 제조방법 |
SI1753764T1 (sl) | 2004-06-09 | 2009-02-28 | Glaxo Group Ltd | Derivati pirolopiridina |
EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
US20090156474A1 (en) | 2004-11-01 | 2009-06-18 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
AU2006253312B2 (en) | 2005-05-30 | 2011-08-18 | Msd K.K. | Novel piperidine derivative |
US20100216758A1 (en) | 2005-08-10 | 2010-08-26 | Makoto Ando | Pyridone Compounds |
EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
CA2619770A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
JP5677717B2 (ja) | 2005-09-14 | 2015-02-25 | 味の素株式会社 | 血行動態改善剤 |
JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
CN101291662A (zh) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
JPWO2007049798A1 (ja) | 2005-10-27 | 2009-04-30 | 萬有製薬株式会社 | 新規ベンゾオキサチイン誘導体 |
AU2006312557B2 (en) | 2005-11-10 | 2011-12-08 | Msd K.K. | Aza-substituted spiro derivative |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
NZ619413A (en) | 2006-05-04 | 2015-08-28 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
US8158617B2 (en) | 2006-05-16 | 2012-04-17 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
CA2664358A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diarylketimine derivative |
CA2675638C (en) | 2007-01-16 | 2015-11-24 | Ipintl, Llc | Composition comprising serotonin for treating metabolic syndrome |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2009063992A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
JPWO2009110510A1 (ja) | 2008-03-06 | 2011-07-14 | Msd株式会社 | アルキルアミノピリジン誘導体 |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
CA2666036C (en) | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
WO2010013595A1 (ja) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体 |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2350010B1 (en) | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療 |
JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
MX357121B (es) | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Proceso de preparacion de agonistas c de guanilato ciclasa. |
CN103781788B (zh) | 2011-07-15 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 经取代的喹唑啉、其制备及其在药物组合物中的用途 |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
WO2016139773A1 (ja) * | 2015-03-04 | 2016-09-09 | 株式会社三洋化学研究所 | シロドシン合成中間体の新規合成方法 |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
KR20190065312A (ko) | 2016-10-14 | 2019-06-11 | 테스 파마 에스.알.엘. | 알파-아미노-베타-카복시뮤콘산 세미알데하이드 데카복실라제의 저해제 |
EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
US20230018413A1 (en) | 2019-08-08 | 2023-01-19 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3250783A (en) * | 1964-09-21 | 1966-05-10 | American Cyanamid Co | Novel pyrrolo (1, 2-alpha) indoles |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
GB8416724D0 (en) | 1984-06-30 | 1984-08-01 | Sorbio Sa Lab | Active compounds |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
EP0252643A1 (en) | 1986-07-01 | 1988-01-13 | BEECHAM - WUELFING GmbH & Co. KG | Pyrido[1,2-a]indole derivatives, process for their preparation and pharmaceutical compounds containing them |
CA1329597C (en) | 1986-12-22 | 1994-05-17 | Dagmar Hoeltje | Derivatives of tetrahydropyrido[1,2-a]indole |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
US5578612A (en) * | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
US5571833A (en) * | 1991-06-21 | 1996-11-05 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-HT1 -like or 5-HT2 receptor agonists |
DE4129779A1 (de) * | 1991-09-07 | 1993-03-11 | Boehringer Mannheim Gmbh | Neue tricyclische thiazol- und oxazol-derivate und diese enthaltende arzneimittel |
GB9207930D0 (en) | 1992-04-10 | 1992-05-27 | Pfizer Ltd | Indoles |
EP0620222A3 (en) | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
TW270114B (es) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
TW403738B (en) | 1994-08-12 | 2000-09-01 | Hoffmann La Roche | Tricyclic pyrazole derivatives |
AU5343298A (en) | 1997-01-13 | 1998-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | 5-ht2c receptor agonists and aminoalkylindazole derivatives |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
TR200100471T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri içeren farmasötik bileşimler |
WO2000009123A1 (en) | 1998-08-14 | 2000-02-24 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors and chitosan |
FR2799757B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2000
- 2000-03-06 EP EP00301814A patent/EP1132389A1/en not_active Withdrawn
-
2001
- 2001-02-27 US US09/794,491 patent/US6583134B2/en not_active Expired - Fee Related
- 2001-03-02 AT AT01911722T patent/ATE326470T1/de not_active IP Right Cessation
- 2001-03-02 JP JP2001565364A patent/JP3828422B2/ja not_active Expired - Fee Related
- 2001-03-02 AU AU4067001A patent/AU4067001A/xx active Pending
- 2001-03-02 BR BR0109044-5A patent/BR0109044A/pt not_active IP Right Cessation
- 2001-03-02 AR ARP010101008A patent/AR029815A1/es unknown
- 2001-03-02 EP EP01911722A patent/EP1274711B1/en not_active Expired - Lifetime
- 2001-03-02 DE DE60119719T patent/DE60119719T2/de not_active Expired - Fee Related
- 2001-03-02 MX MXPA02008689A patent/MXPA02008689A/es active IP Right Grant
- 2001-03-02 CA CA002399111A patent/CA2399111A1/en not_active Abandoned
- 2001-03-02 ES ES01911722T patent/ES2263595T3/es not_active Expired - Lifetime
- 2001-03-02 KR KR1020027011649A patent/KR100554817B1/ko not_active IP Right Cessation
- 2001-03-02 AU AU2001240670A patent/AU2001240670B2/en not_active Ceased
- 2001-03-02 CN CNB018054730A patent/CN1281608C/zh not_active Expired - Fee Related
- 2001-03-02 WO PCT/EP2001/002388 patent/WO2001066548A1/en active IP Right Grant
-
2002
- 2002-08-02 ZA ZA200206198A patent/ZA200206198B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR0109044A (pt) | 2003-06-03 |
JP2003525941A (ja) | 2003-09-02 |
EP1274711A1 (en) | 2003-01-15 |
CA2399111A1 (en) | 2001-09-13 |
CN1281608C (zh) | 2006-10-25 |
US6583134B2 (en) | 2003-06-24 |
EP1132389A1 (en) | 2001-09-12 |
JP3828422B2 (ja) | 2006-10-04 |
AU2001240670B2 (en) | 2006-03-09 |
ZA200206198B (en) | 2003-11-03 |
KR20020084169A (ko) | 2002-11-04 |
CN1404483A (zh) | 2003-03-19 |
AU4067001A (en) | 2001-09-17 |
ES2263595T3 (es) | 2006-12-16 |
ATE326470T1 (de) | 2006-06-15 |
WO2001066548A1 (en) | 2001-09-13 |
MXPA02008689A (es) | 2003-02-24 |
KR100554817B1 (ko) | 2006-02-22 |
DE60119719D1 (de) | 2006-06-22 |
EP1274711B1 (en) | 2006-05-17 |
US20010025039A1 (en) | 2001-09-27 |
DE60119719T2 (de) | 2007-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR029815A1 (es) | Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento | |
UY27097A1 (es) | Derivados del indol | |
DK1109813T3 (da) | Pyrroloindoler, pyridoindoler og azepinoindoler som 5-HT2C-agonister | |
AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
GT200100183A (es) | Derivados de quinolina y quinazolina. | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
NO20062139L (no) | Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister | |
UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
TW200621762A (en) | Novel compounds | |
TW200716595A (en) | Chromane and chromene derivatives and uses thereof | |
AR038762A1 (es) | Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento | |
TW200617001A (en) | Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same | |
UY28805A1 (es) | Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso par tratar la diabetes y trastornos relacionados | |
UY28150A1 (es) | Agentes terapeuticos | |
ATE370138T1 (de) | Neue imidazopyridine und ihre verwendung | |
ECSP045073A (es) | Nuevos derivados de piperazina | |
ES2340502T3 (es) | Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad. | |
PT1109809E (pt) | Pirroloquinolinas para tratamento da obesidade | |
AR050711A1 (es) | Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central | |
UY27204A1 (es) | Derivados de pieracina | |
DE69930397D1 (de) | Indazolderivate mit 5-ht2-rezeptor-aktivität | |
AR040960A1 (es) | Derivados de tiazol | |
AR035685A1 (es) | Derivados de isoxazolina, sus prodrogas, composiciones farmaceuticas que comprenden dichos compuestos, procesos para preparar dichas composiciones, uso de dichos compuestos para la fabricacion de medicamentos, uso de dichas composiciones para la fabricacion de medicamentos, procesos para la preparac | |
MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
AR040239A1 (es) | Tiofenos sustituidos, metodos para su preparacion, su uso para preparar un medicamento y medicamentos que los comprenden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |